home / stock / agle / agle news

AGLE News and Press, Aeglea BioTherapeutics Inc. From 04/30/20

Stock Information
Company Name: Aeglea BioTherapeutics Inc.
Stock Symbol: AGLE
Market: NASDAQ
Website: aegleabio.com
Menu
AGLE AGLE Quote AGLE Short AGLE News AGLE Articles AGLE Message Board
Get AGLE Alerts

News, Short Squeeze, Breakout and More Instantly...
AGLE - Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

AUSTIN, Texas, April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for rare and other high-burden diseases, today announced the closing of its public offering ...
AGLE - Aeglea Bio up 10% premarket after pricing equity offering

Aeglea BioTherapeutics (NASDAQ: AGLE ) has priced its public offering of 11,652,830 common shares at $4.75/share. More news on: Aeglea BioTherapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

AGLE - Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering

AUSTIN, Texas, April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced the pricing of an underw...

AGLE - Aeglea -5% amid $100M equity offering

Aeglea BioTherapeutics (NASDAQ: AGLE ) is 5% lower postmarket after word that it's filed to offer $100M in equity. More news on: Aeglea BioTherapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

AGLE - Aeglea BioTherapeutics Announces Proposed Public Offering

AUSTIN, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced a proposed underwritten...

AGLE - Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Tria...

AGLE - Aeglea BioTherapeutics EPS beats by $0.03

Aeglea BioTherapeutics (NASDAQ: AGLE ): FY GAAP EPS of -$2.45 beats by $0.03 . More news on: Aeglea BioTherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

AGLE - Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones

Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Quarter of 2020, with Topline Data Expected in First Quarter of 2021 Phase 1/2 Trial for Patients with Homocystinuria to Initiate in Second Quarter of 2020 AUSTIN, Texas, Feb. 2...

AGLE - Aeglea Bio Therapeutics (AGLE) Investor Presentation - Slideshow

The following slide deck was published by Aeglea BioTherapeutics, Inc. in conjunction with this Read more ...

AGLE - Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

AUSTIN, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced it has filed a Clinical Trial Appl...
Previous 10 Next 10